- AZD1446, a product candidate being pursued in collaboration with AstraZeneca, scheduled for Tuesday, October 16 at 10:00 a.m. Eastern Time; and
- TC-8831, a late preclinical product candidate for Parkinson’s disease or L-dopa-induced dyskinesia, scheduled for Sunday, October 14 at 8:00 a.m. and 10:00 a.m. Eastern Time.
Forward-Looking StatementsThis press release includes “forward-looking statements” made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements other than statements of historical fact regarding, without limitation: presentations by Targacept scientists at the 42nd annual meeting of the Society for Neuroscience; the medical benefits of NNR Therapeutics; or Targacept’s plans and expectations. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various important factors, including without limitation the conduct and results of clinical trials or non-clinical studies and assessments of AZD1446, TC-8831 and other Targacept product candidates; Targacept’s ability to protect its intellectual property; and the timing and success of submission, acceptance and approval of regulatory filings. These and other risks and uncertainties are described in greater detail under the heading “Risk Factors” in Targacept’s most recent Annual Report on Form 10-K and in other filings that it makes with the Securities and Exchange Commission. As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. Targacept cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Targacept’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Targacept disclaims any obligation to update any forward-looking statement, except as required by applicable law. NNR Therapeutics™ and Building Health, Restoring Independence® are trademarks or service marks of Targacept, Inc. Any other service marks, trademarks and trade names appearing in this press release are the properties of their respective owners.